There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on InflaRx (IFRX), Penumbra (PEN) and Bluebird Bio (BLUE) with bullish sentiments.
InflaRx (IFRX)
H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx today and set a price target of $12.00. The company’s shares closed last Monday at $5.74.
According to TipRanks.com, White is a top 100 analyst with an average return of 52.4% and a 59.9% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for InflaRx with a $10.75 average price target.
See today’s analyst top recommended stocks >>
Penumbra (PEN)
In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Penumbra, with a price target of $204.00. The company’s shares closed last Monday at $206.23.
According to TipRanks.com, Plovanic is a 3-star analyst with an average return of 4.5% and a 53.1% success rate. Plovanic covers the Healthcare sector, focusing on stocks such as Staar Surgical Company, Merit Medical Systems, and Edwards Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Penumbra with a $237.25 average price target.
Bluebird Bio (BLUE)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Bluebird Bio, with a price target of $86.00. The company’s shares closed last Monday at $50.40.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 28.6% and a 51.3% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics, and Atara Biotherapeutics.
Bluebird Bio has an analyst consensus of Moderate Buy, with a price target consensus of $75.93, representing a 53.1% upside. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
